Summary
Mitoxantrone, an anthracenedione derivative, was administered by members of the Southwest Oncology Group to thirty patients with metastatic malignant melanoma. The drug was administered as an intravenous infusion over 30 min at a starting dose of 12 mg/m2 and repeated every three weeks. Myelosuppression was the major toxicity. As administered, mitoxantrone is not an effective agent in the treatment of malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zee-Cheng RKY, Cheng CC: Antineoplastic agents. Structure activity relationship study of bis (substituted animoalkyeamine) anthraquinones. J Med Chem 21:291–294, 1979
Johnson RK, Zee-Cheng RKY, Lee WW, Action FN, Henry DW, Cheng CC: Experimental antitumor activity of amino anthraquinones. Cancer Treatment Rep 63:425–439, 1979
Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr: Phase I clinical investigation of 1,4-Dihydroxy-5,8-bis [[2-([2-hydroxyethyl) amino] ethyl]] amino 9,10-anthracenedione dihydrochloride (NSC 301739, DHAD) a new anthracenedione. Cancer Research 40:1516–1518, May, 1980
Author information
Authors and Affiliations
Additional information
Address for reprints: Southwest Oncology Group (SWOG-8065), Operations Office, 4450 Medical Drive, San Antonio, TX, 78229, U.S.A.
Rights and permissions
About this article
Cite this article
Taylor, S.A., Tranum, B.T., Von Hoff, D.D. et al. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. Invest New Drugs 3, 67–69 (1985). https://doi.org/10.1007/BF00176827
Issue Date:
DOI: https://doi.org/10.1007/BF00176827